Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lenz G, Trněný M, Burke JM, Nowakowski GS, Fox CP, Chiappella A, Duell J, Jeon YW, Cheah CY, Westin J, Ye JZ, Caguioa PB, Belada D, Shin HJ, Oh SY, Amorim S, Ku M, Mocikova H, Jiménez JL, Gaidano G, Rosenwald A, Chiarle R, Colucci P, Ioannidis S, Cheng L, Vitolo U, frontMIND Study Investigators

Open source

DOI: 10.1016/s0140-6736(26)00866-4
Published: 2026 Jun 20
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00866-4,
  title = {Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.},
  author = {Lenz G and Trněný M and Burke JM and Nowakowski GS and Fox CP and Chiappella A and Duell J and Jeon YW and Cheah CY and Westin J and Ye JZ and Caguioa PB and Belada D and Shin HJ and Oh SY and Amorim S and Ku M and Mocikova H and Jiménez JL and Gaidano G and Rosenwald A and Chiarle R and Colucci P and Ioannidis S and Cheng L and Vitolo U and frontMIND Study Investigators},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00866-4},
  url = {https://doi.org/10.1016/s0140-6736(26)00866-4}
}

RIS

TY  - JOUR
TI  - Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
AU  - Lenz G
AU  - Trněný M
AU  - Burke JM
AU  - Nowakowski GS
AU  - Fox CP
AU  - Chiappella A
AU  - Duell J
AU  - Jeon YW
AU  - Cheah CY
AU  - Westin J
AU  - Ye JZ
AU  - Caguioa PB
AU  - Belada D
AU  - Shin HJ
AU  - Oh SY
AU  - Amorim S
AU  - Ku M
AU  - Mocikova H
AU  - Jiménez JL
AU  - Gaidano G
AU  - Rosenwald A
AU  - Chiarle R
AU  - Colucci P
AU  - Ioannidis S
AU  - Cheng L
AU  - Vitolo U
AU  - frontMIND Study Investigators
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00866-4
UR  - https://doi.org/10.1016/s0140-6736(26)00866-4
ER  -

APA

G, L., M, T., JM, B., GS, N., CP, F., A, C., J, D., YW, J., CY, C., J, W., JZ, Y., PB, C., D, B., HJ, S., SY, O., S, A., M, K., H, M., JL, J., G, G., A, R., R, C., P, C., S, I., L, C., U, V., & Investigators, F. S. (2026). Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00866-4

Source records

pubmed · retrieved 2026-09-26T12:56:27.204Z